Insider transactions

EDGAR

XOMA Corp

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-16.

Open-market purchases (code P)
1 transactions, 100,000 shares
Sum of shares × price per share: 2,505,000
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 121

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-07-14 Filed 2026-07-16BVF PARTNERS L P/IL 10% ownerBIOTECHNOLOGY VALUE FUND L P 10% ownerBVF I GP LLC 10% ownerBIOTECHNOLOGY VALUE FUND II LP 10% ownerBVF II GP LLC 10% ownerBiotechnology Value Trading Fund OS LP Other: See Explanation of ResponsesBVF Partners OS Ltd. Other: See Explanation of ResponsesBVF GP HOLDINGS LLC 10% ownerBVF INC/IL 10% ownerLAMPERT MARK N 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock, $0.0075 par value per share
Disposed (D)3,635,758——0Direct (D) No
F1, F2, F7, F3
  • F1 This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), BVF Partners OS Ltd. (Partners OS), BVF I GP LLC (BVF GP), BVF II GP LLC (BVF2 GP), BVF GP Holdings LLC (BVF GPH), BVF Partners L.P. (Partners), BVF Inc. and Mark N. Lampert (collectively, the Reporting Persons). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  • F2 This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among the Issuer, Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the Merger).
  • F7 The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments.
  • F3 Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
Open filing 0000921895-26-001823 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-16BVF PARTNERS L P/IL 10% ownerBIOTECHNOLOGY VALUE FUND L P 10% ownerBVF I GP LLC 10% ownerBIOTECHNOLOGY VALUE FUND II LP 10% ownerBVF II GP LLC 10% ownerBiotechnology Value Trading Fund OS LP Other: See Explanation of ResponsesBVF Partners OS Ltd. Other: See Explanation of ResponsesBVF GP HOLDINGS LLC 10% ownerBVF INC/IL 10% ownerLAMPERT MARK N 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock, $0.0075 par value per share
Disposed (D)2,773,545——0Direct (D) No
F1, F2, F7, F4
  • F1 This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), BVF Partners OS Ltd. (Partners OS), BVF I GP LLC (BVF GP), BVF II GP LLC (BVF2 GP), BVF GP Holdings LLC (BVF GPH), BVF Partners L.P. (Partners), BVF Inc. and Mark N. Lampert (collectively, the Reporting Persons). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  • F2 This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among the Issuer, Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the Merger).
  • F7 The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments.
  • F4 Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
Open filing 0000921895-26-001823 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-16BVF PARTNERS L P/IL 10% ownerBIOTECHNOLOGY VALUE FUND L P 10% ownerBVF I GP LLC 10% ownerBIOTECHNOLOGY VALUE FUND II LP 10% ownerBVF II GP LLC 10% ownerBiotechnology Value Trading Fund OS LP Other: See Explanation of ResponsesBVF Partners OS Ltd. Other: See Explanation of ResponsesBVF GP HOLDINGS LLC 10% ownerBVF INC/IL 10% ownerLAMPERT MARK N 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock, $0.0075 par value per share
Disposed (D)412,000——0Direct (D) No
F1, F2, F7, F5
  • F1 This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), BVF Partners OS Ltd. (Partners OS), BVF I GP LLC (BVF GP), BVF II GP LLC (BVF2 GP), BVF GP Holdings LLC (BVF GPH), BVF Partners L.P. (Partners), BVF Inc. and Mark N. Lampert (collectively, the Reporting Persons). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  • F2 This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among the Issuer, Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the Merger).
  • F7 The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments.
  • F5 Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
Open filing 0000921895-26-001823 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-16BVF PARTNERS L P/IL 10% ownerBIOTECHNOLOGY VALUE FUND L P 10% ownerBVF I GP LLC 10% ownerBIOTECHNOLOGY VALUE FUND II LP 10% ownerBVF II GP LLC 10% ownerBiotechnology Value Trading Fund OS LP Other: See Explanation of ResponsesBVF Partners OS Ltd. Other: See Explanation of ResponsesBVF GP HOLDINGS LLC 10% ownerBVF INC/IL 10% ownerLAMPERT MARK N 10% owner
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock, $0.0075 par value per share
Disposed (D)772,000——0Indirect (I) See footnoteNo
F1, F2, F7, F6
  • F1 This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), BVF Partners OS Ltd. (Partners OS), BVF I GP LLC (BVF GP), BVF II GP LLC (BVF2 GP), BVF GP Holdings LLC (BVF GPH), BVF Partners L.P. (Partners), BVF Inc. and Mark N. Lampert (collectively, the Reporting Persons). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  • F2 This Form 4 reports securities disposed of pursuant to an Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among the Issuer, Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo), pursuant to which, among other things, the Parent acquired all of the outstanding shares of the common stock of the Issuer, effective July 14, 2026 (the Merger).
  • F7 The Reporting Persons received the following in exchange for each share of the Issuer's common stock disposed of in connection with the Merger: $39.00 in cash per share of common stock and an amount of contingent value rights per share of common stock for potential cash payments.
  • F6 Securities held in certain Partners managed accounts (the Partners Managed Accounts). Partners, as the investment manager of the Partners Managed Accounts, may be deemed to beneficially own the securities held by the Partners Managed Accounts. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Accounts. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Accounts.
Open filing 0000921895-26-001823 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hughes Owen Director · Officer: Chief Executive Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)191,264——0Direct (D) No
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
Open filing 0001193125-26-303725 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hughes Owen Director · Officer: Chief Executive Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)752——0Indirect (I) By 401(k) PlanNo
F1, F2
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
Open filing 0001193125-26-303725 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Depositary Shares - 8.375% Series B Cumulative Stock
Disposed (D)102,000——0Direct (D) No
F1, F4
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
Open filing 0001193125-26-303725 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (100,000) — exercise price 18.66
Disposed (D)100,0000—0Direct (D) No
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303725 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (75,000) — exercise price 30
Disposed (D)75,0000—0Direct (D) No
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303725 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance Stock Units — underlying Common Stock (116,245)
Disposed (D)116,2450—0Direct (D) No
F1, F7, F8
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F7 Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award (PSU) automatically converted into and was substituted with a restricted stock unit award (each, a Converted PSU) with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the Target Shares (as the term Target Shares is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of Target Shares as to which, as of immediately prior to the Effective Time, the Performance-Requirement has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the Target Shares underlying such PSU as to which the Performance-Requirement would be satisfied if the Closing Price (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over
  • F8 (Continued from footnote 7) (B) the number of Target Shares as to which, as of immediately prior to the Effective Time, the Performance-Requirement has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU.
Open filing 0001193125-26-303725 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hughes Owen Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance Stock Units — underlying Common Stock (132,714)
Disposed (D)132,7140—0Direct (D) No
F1, F7, F8
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F7 Immediately prior to the Effective Time, pursuant to the Merger Agreement, each outstanding performance stock unit award (PSU) automatically converted into and was substituted with a restricted stock unit award (each, a Converted PSU) with respect to a number of Shares equal to either (x) for each PSU granted on or after March 1, 2026, the excess of (A) 100% of the Target Shares (as the term Target Shares is defined and set forth in the applicable award agreement governing such PSU) underlying such PSU over (B) the number of Target Shares as to which, as of immediately prior to the Effective Time, the Performance-Requirement has been achieved, or (y) for each PSU granted prior to March 1, 2026, the excess of (A) the percentage of the Target Shares underlying such PSU as to which the Performance-Requirement would be satisfied if the Closing Price (as defined in the applicable award agreement governing such PSU) were equal to the Closing Amount over
  • F8 (Continued from footnote 7) (B) the number of Target Shares as to which, as of immediately prior to the Effective Time, the Performance-Requirement has been achieved. Immediately prior to the Effective Time, each Converted PSU was automatically cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required tax withholding, equal to the product of (i) the number of Shares subject to such Converted PSU and (ii) the Closing Amount, and (B) one CVR for each Share subject to such Converted PSU.
Open filing 0001193125-26-303725 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Franklin Heather L Director
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)6,269——0Direct (D) No
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
Open filing 0001193125-26-303719 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Franklin Heather L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (17,282) — exercise price 31.39
Disposed (D)17,2820—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303719 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Franklin Heather L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,996) — exercise price 17.86
Disposed (D)8,9960—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303719 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Franklin Heather L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,967) — exercise price 21.39
Disposed (D)10,9670—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303719 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Franklin Heather L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,763) — exercise price 24.71
Disposed (D)9,7630—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303719 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Kosacz Barbara Director
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)6,269——0Direct (D) No
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
Open filing 0001193125-26-303726 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (19,979) — exercise price 12.65
Disposed (D)19,9790—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303726 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,167) — exercise price 15.59
Disposed (D)8,1670—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303726 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (6,152) — exercise price 21.27
Disposed (D)6,1520—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303726 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (5,101) — exercise price 31.04
Disposed (D)5,1010—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303726 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,996) — exercise price 17.86
Disposed (D)8,9960—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303726 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,967) — exercise price 21.39
Disposed (D)10,9670—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303726 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Kosacz Barbara Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,763) — exercise price 24.71
Disposed (D)9,7630—0Direct (D) No
F1, F4, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F5 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303726 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)9,532——0Direct (D) No
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

8.625% Series A Cumulative Perpetual Preferred Stock
Disposed (D)10,000——0Direct (D) No
F1, F4
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Depositary Shares - 8.375% Series B Cumulative Stock
Disposed (D)20,000——0Direct (D) No
F1, F5
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,000) — exercise price 4.03
Disposed (D)8,0000—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,366) — exercise price 19.4
Disposed (D)2,3660—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (5,052) — exercise price 25.16
Disposed (D)5,0520—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,167) — exercise price 15.59
Disposed (D)8,1670—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (6,152) — exercise price 21.27
Disposed (D)6,1520—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (5,101) — exercise price 31.04
Disposed (D)5,1010—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,996) — exercise price 17.86
Disposed (D)8,9960—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,967) — exercise price 21.39
Disposed (D)10,9670—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,763) — exercise price 24.71
Disposed (D)9,7630—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14LIMBER JOSEPH M Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (9,936) — exercise price 25.12
Disposed (D)9,9360—0Direct (D) No
F1, F6, F7
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F7 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303727 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hernday Natasha Director
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)9,304——0Direct (D) No
F1, F2, F3
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F2 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F3 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
Open filing 0001193125-26-303723 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

8.625% Series A Cumulative Perpetual Preferred Stock
Disposed (D)4,000——0Direct (D) No
F1, F4
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F4 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
Open filing 0001193125-26-303723 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (13,251) — exercise price 19.76
Disposed (D)13,2510—0Direct (D) No
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303723 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (5,101) — exercise price 31.04
Disposed (D)5,1010—0Direct (D) No
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303723 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (8,996) — exercise price 17.86
Disposed (D)8,9960—0Direct (D) No
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303723 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,967) — exercise price 21.39
Disposed (D)10,9670—0Direct (D) No
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303723 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Hernday Natasha Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,881) — exercise price 24.71
Disposed (D)4,8810—0Direct (D) No
F1, F5, F6
  • F1 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a Company Stock Option) that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a Terminating Company Stock Option) became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
  • F6 As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Open filing 0001193125-26-303723 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Sitko Bradley Officer: Chief Investment Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)83,765——0Direct (D) No
F1, F2, F3, F4
  • F1 Includes 804 shares acquired under the ESPP Plan on May 31, 2026.
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F3 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
  • F4 At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit (RSU) became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
Open filing 0001193125-26-303722 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Sitko Bradley Officer: Chief Investment Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

8.625% Series A Cumulative Perpetual Preferred Stock
Disposed (D)313——0Direct (D) No
F2, F5
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F5 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
Open filing 0001193125-26-303722 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Sitko Bradley Officer: Chief Investment Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Depositary Shares - 8.375% Series B Cumulative Stock
Disposed (D)7,045——0Direct (D) No
F2, F6
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F6 Prior to the Effective Time, pursuant to the Merger Agreement, each issued and outstanding share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share, of the Issuer (including the Depositary Shares) was redeemed by the Issuer in accordance with the terms of the certificate of designation governing such stock, including payment of all accrued and unpaid dividends thereon through the date of such redemption.
Open filing 0001193125-26-303722 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Sitko Bradley Officer: Chief Investment Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)1,287——0Indirect (I) By 401(k)No
F2, F3
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F3 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
Open filing 0001193125-26-303722 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Sitko Bradley Officer: Chief Investment Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)75——0Indirect (I) By childNo
F2, F3
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F3 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
Open filing 0001193125-26-303722 Read from the filing’s XML Dispute this row
2026-07-14 Filed 2026-07-14Sitko Bradley Officer: Chief Investment Officer
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)75——0Indirect (I) By childNo
F2, F3
  • F2 Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the Merger Agreement), by and among XOMA Royalty Corporation (the Issuer), Ligand Pharmaceuticals Incorporated (Parent), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent (Merger Sub), and XOMA Royalty Holdings Corporation (HoldCo). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the Merger), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the Issuer refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
  • F3 At the time the Merger became effective (the Effective Time), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the Shares) (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the Closing Amount), plus (ii) an amount of contingent value rights (each, a CVR) representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the Merger Consideration).
Open filing 0001193125-26-303722 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–1 of 1

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Allworth Financial LP 21 SH893 dollarsUnchanged Prior quarter: 21Open filing 0001140361-26-042358 Filed 2026-11-06 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • BVF INC/IL 7,593,303 SH
  • MORGAN STANLEY 1,697,167 SH
  • FMR LLC 1,605,532 SH
  • Woodline Partners LP 1,114,363 SH
  • Newtyn Management, LLC 709,247 SH
  • BlackRock, Inc. 691,971 SH
  • VANGUARD CAPITAL MANAGEMENT LLC 505,165 SH
  • Opaleye Management Inc. 338,374 SH
  • GEODE CAPITAL MANAGEMENT, LLC 245,321 SH
  • WATER ISLAND CAPITAL LLC 242,000 SH
  • ALPINE ASSOCIATES MANAGEMENT INC. 239,318 SH
  • STATE STREET CORP 197,764 SH
  • MILLENNIUM MANAGEMENT LLC 196,307 SH
  • DIMENSIONAL FUND ADVISORS LP 177,106 SH
  • HSBC HOLDINGS PLC 149,523 SH
  • NORTHERN TRUST CORP 96,179 SH
  • VANGUARD PORTFOLIO MANAGEMENT LLC 90,348 SH
  • TUDOR INVESTMENT CORP ET AL 84,391 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 83,623 SH
  • TORNO CAPITAL, LLC 80,000 SH
  • Bank of New York Mellon Corp 75,348 SH
  • Verition Fund Management LLC 70,601 SH
  • VANGUARD FIDUCIARY TRUST CO 70,189 SH
  • Simcoe Capital LLC 68,053 SH
  • Groupe la Francaise 52,276 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 50,400 SH
  • TLS Advisors LLC 42,165 SH
  • TORNO CAPITAL, LLC 41,000 SH
  • TWO SIGMA INVESTMENTS, LP 36,744 SH
  • XTX Topco Ltd 35,046 SH
  • CREDIT INDUSTRIEL ET COMMERCIAL 34,853 SH
  • Balyasny Asset Management L.P. 34,621 SH
  • JANE STREET GROUP, LLC 32,100 SH
  • MILLENNIUM MANAGEMENT LLC 30,200 SH
  • JPMORGAN CHASE CO 30,018 SH
  • RBF Capital, LLC 30,000 SH
  • CITADEL ADVISORS LLC 28,460 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 28,078 SH
  • Sixth Street Partners Management Company, L.P. 28,078 SH
  • EQUITEC PROPRIETARY MARKETS, LLC 28,000 SH
  • GROUP ONE TRADING LLC 27,200 SH
  • SIERRA SUMMIT ADVISORS LLC 25,740 SH
  • UBS Group AG 23,843 SH
  • GOLDMAN SACHS GROUP INC 20,122 SH
  • CSS LLC/IL 19,561 SH
  • TORNO CAPITAL, LLC 18,700 SH
  • Nuveen, LLC 18,388 SH
  • JANE STREET GROUP, LLC 18,192 SH
  • MARTINGALE ASSET MANAGEMENT L P 12,200 SH
  • RHUMBLINE ADVISERS 11,451 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Morgan Stanley Common Stock0.0007/31/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 4Open filing 0000895421-26-000217 Dispute this row
Morgan Stanley Investment Management Inc. Common Stock0007/31/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 4Open filing 0000895421-26-000217 Dispute this row
FMR LLC COMMON STOCK0.00.0007/31/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 7Open filing 0000315066-26-002250 Dispute this row
Abigail P. Johnson COMMON STOCK0.00.0007/31/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 7Open filing 0000315066-26-002250 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
BVF I GP LLC Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
BVF II GP LLC Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
BVF INC/IL Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
LAMPERT MARK N Common Stock, $0.0075 par value00.0007/14/2026 Filed 2026-07-16SCHEDULE 13D/AAmendment 15Open filing 0000921895-26-001822 Dispute this row
Morgan Stanley Common Stock9.51,686,49506/30/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 3Open filing 0000895421-26-000216 Dispute this row
Morgan Stanley Investment Management Inc. Common Stock9.51,685,49306/30/2026 Filed 2026-08-07SCHEDULE 13G/AAmendment 3Open filing 0000895421-26-000216 Dispute this row
FMR LLC COMMON STOCK9.11,605,532.1406/30/2026 Filed 2026-08-06SCHEDULE 13G/AAmendment 6Open filing 0000315066-26-002202 Dispute this row
Abigail P. Johnson COMMON STOCK9.11,605,532.1406/30/2026 Filed 2026-08-06SCHEDULE 13G/AAmendment 6Open filing 0000315066-26-002202 Dispute this row
Vanguard Capital Management Common Stock3.23571,82306/30/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 1Open filing 0002100119-26-001505 Dispute this row
BlackRock, Inc. Common Stock3.9685,77206/30/2026 Filed 2026-07-30SCHEDULE 13G/AAmendment 1Open filing 0002012383-26-003132 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0075 par value20.73,635,758.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
BVF I GP LLC Common Stock, $0.0075 par value20.73,635,758.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0075 par value15.82,773,545.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
BVF II GP LLC Common Stock, $0.0075 par value15.82,773,545.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.0075 par value2.3412,000.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.0075 par value2.3412,000.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.0075 par value36.56,409,303.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.0075 par value43.37,593,303.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
BVF INC/IL Common Stock, $0.0075 par value43.37,593,303.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
LAMPERT MARK N Common Stock, $0.0075 par value43.37,593,303.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 14Open filing 0000921895-26-001434 Dispute this row
Ligand Pharmaceuticals Incorporated Common Stock, par value $0.0075 per share47.08,062,678.0004/27/2026 Filed 2026-05-01SCHEDULE 13DOpen filing 0001193125-26-202033 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0075 par value10.91,322,758.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
BVF I GP LLC Common Stock, $0.0075 par value10.91,322,758.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0075 par value10.51,267,545.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
BVF II GP LLC Common Stock, $0.0075 par value10.51,267,545.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.0075 par value00.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.0075 par value00.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.0075 par value21.42,590,303.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.0075 par value21.42,590,303.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
BVF INC/IL Common Stock, $0.0075 par value21.42,590,303.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
LAMPERT MARK N Common Stock, $0.0075 par value21.42,590,303.0004/27/2026 Filed 2026-04-29SCHEDULE 13D/AAmendment 13Open filing 0000921895-26-001116 Dispute this row
Woodline Partners LP Common Stock, par value $0.00755.4640,001.0003/31/2026 Filed 2026-05-15SCHEDULE 13GOpen filing 0000919574-26-003229 Dispute this row
Vanguard Capital Management Common Stock5.15613,45803/31/2026 Filed 2026-04-30SCHEDULE 13GOpen filing 0002100119-26-001264 Dispute this row
BlackRock, Inc. Common Stock5.4640,54903/31/2026 Filed 2026-04-27SCHEDULE 13GOpen filing 0002012383-26-001729 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-27SCHEDULE 13G/AAmendment 1Open filing 0000102909-26-002623 Dispute this row
FMR LLC COMMON STOCK10.21,268,506.1402/27/2026 Filed 2026-03-06SCHEDULE 13G/AAmendment 5Open filing 0000315066-26-000644 Dispute this row
Abigail P. Johnson COMMON STOCK10.21,268,506.1402/27/2026 Filed 2026-03-06SCHEDULE 13G/AAmendment 5Open filing 0000315066-26-000644 Dispute this row
Morgan Stanley Common Stock13.71,702,54512/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0000895421-26-000069 Dispute this row
Morgan Stanley Investment Management Inc. Common Stock13.71,700,92512/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 2Open filing 0000895421-26-000069 Dispute this row
FMR LLC COMMON STOCK9.01,079,588.1406/30/2025 Filed 2025-08-06SCHEDULE 13G/AAmendment 4Open filing 0000315066-25-002157 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,094,807 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024187,785
2025235,520
2026254,737

Filings made before the SEC required XML are listed, not extracted.

Back to XOMA Corp